Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study

In preclinical models, temozolomide, and vincristine are additive or synergistic with irinotecan. We examined this three‐drug combination in children with relapsed solid tumors. Patients received orally administered irinotecan together with temozolomide and vincristine on two different schedules, using cefixime to reduce irinotecan‐associated diarrhea.

[1]  P. Houghton,et al.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors , 2004, Cancer Chemotherapy and Pharmacology.

[2]  P. Houghton,et al.  Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors , 2004, Clinical Cancer Research.

[3]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Houghton,et al.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Verweij,et al.  Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors , 2005, Clinical Cancer Research.

[6]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[7]  S. Groshen,et al.  Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[9]  S. Donaldson,et al.  Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression , 2008 .

[10]  S. Clarke,et al.  Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction , 2001, Anti-cancer drugs.

[11]  M. Carli,et al.  Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma , 2006, Cancer.

[12]  N. Cheung,et al.  Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Piccart,et al.  A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  P. Houghton,et al.  Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  D. V. Von Hoff,et al.  Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Beth McCarville,et al.  Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma , 2007, Pediatric blood & cancer.

[17]  Soma Das,et al.  Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Richel,et al.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.

[19]  P. Houghton,et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Panetta,et al.  UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Houghton,et al.  Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Ratain,et al.  The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity , 2007, Journal of clinical pharmacology.

[23]  M. Tan,et al.  Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Mandrekar,et al.  A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7) , 2005 .

[25]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[27]  P. Houghton,et al.  Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  K. McHugh,et al.  Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Société Française des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Wexler,et al.  Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience , 2009, Pediatric blood & cancer.

[30]  A. Pappo,et al.  Reducing irinotecan‐associated diarrhea in children , 2008, Pediatric blood & cancer.